SLC22A2 and in situ carcinoma: The two cancer cell lines, Huh7 (OCT2-negative) and MDA-MB-468 (OCT2-positive), were treated with a wide range of either CIS (0.001 to 25 μM) or CIM (0.1 to 10 mM) concentrations for 72 h.